Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1438 participants.
Also called NCT01785472
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,438 participants
- Sponsor
- Registry
-
NCT01785472
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Hong Kong SAR China, Philippines, Singapore, South Korea, Taiwan, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT01785472. Randomized; double masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-09-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- Olmesartan
- Intervention (Drug)
- Placebo of LCZ696
- Intervention (Drug)
- Placebo of Olmesartan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01785472- Content hash
d94893ab9977fb854177b0c9716d9d179e03ab08e39178485bc7c8470106568a